Chief Financial Officer · LeonaBio, Inc. · Athira Pharma, Inc.
Side
SELL
Value
$2,043
Shares
297
Price
$6.88
Executed
Jan 2, 2026
Disclosed
Jan 5, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Jan 2 executedJan 5, 2026 disclosed
ATHA · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events+10 / 10
Officer or director change · Other material event filed 7 days after the trade (8-K)
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Renninger Robert filed this Form 4 reporting a open-market sale of ATHA on Jan 2, 2026. It became public on Jan 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Renninger Robertcik:0002037968
Issuer
LeonaBio, Inc.cik:0001620463
Revision history · 0
No field has changed since this record was first ingested.
An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.
